Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Business Wire September 17, 2024

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

PR Newswire June 13, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Accesswire June 11, 2024

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

PR Newswire March 14, 2024

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PR Newswire September 12, 2023

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire September 6, 2023

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

PR Newswire August 1, 2023

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

PR Newswire June 8, 2023

Protalix BioTherapeutics set to join Russell 3000® Index

PR Newswire May 23, 2023

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

PR Newswire May 18, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

PR Newswire May 10, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

PR Newswire May 5, 2023

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

PR Newswire February 27, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

PR Newswire February 24, 2023

Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium(TM) 2023

PR Newswire February 21, 2023

Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023

PR Newswire February 21, 2023

Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102

PR Newswire December 4, 2022

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

TheNewsWire November 30, 2022

Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results

PR Newswire November 14, 2022

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

TheNewsWire September 21, 2022